



## Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

February 7, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2023-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX), today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the SVB Securities Global Biopharma Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesday, February 14, 2023, at 10:00am ET.

A live webcast of the presentation can be accessed under "Events" in the Investor section of the Company's website, <https://investors.amylyx.com/news-events/events>, and will be available for replay for 90 days following the event.

### About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit [amylyx.com](https://amylyx.com) and follow us on [LinkedIn](#) and [Twitter](#). For investors, please visit [investors.amylyx.com](https://investors.amylyx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230207005048/en/): <https://www.businesswire.com/news/home/20230207005048/en/>

#### Media

Amylyx Media Team  
+1 (857) 799-7274  
[amylyxmediateam@amylyx.com](mailto:amylyxmediateam@amylyx.com)

#### Investors

Lindsey Allen  
Amylyx Pharmaceuticals, Inc.  
+1 (857) 320-6244  
[investors@amylyx.com](mailto:investors@amylyx.com)

Source: Amylyx Pharmaceuticals, Inc.